Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025990 | 0.81 | GAA (0.37) | MAPTALDH1A1CYP3A4CYP1A2TSHR | |
| SCHEMBL16213299 | 0.81 | MAPT (0.38) | TYMSMAPTALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL1028170 | 0.79 | TSHR (0.38) | MAPTALDH1A1CYP3A4CYP1A2TSHR | |
| SCHEMBL4143975 | 0.78 | VCAM1 (0.39) | MAPTALDH1A1CYP3A4CYP1A2TSHR | |
| SCHEMBL31574827 | 0.78 | NQO2 (0.46) | MAPTALDH1A1CYP3A4BLMKDM4E | |
| SCHEMBL16213641 | 0.78 | PIM1 (0.40) | MAPTALDH1A1CYP3A4CYP1A2TSHR | |
| SCHEMBL6486222 | 0.76 | JAK2 (0.45) | TYMSMAPTALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL31620407 | 0.76 | MAPT (0.42) | MAPTALDH1A1CYP3A4CYP1A2TSHR | |
| SCHEMBL22655651 | 0.75 | MAPT (0.39) | TYMSMAPTALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL30554364 | 0.73 | MAPT (0.44) | MAPTALDH1A1CYP3A4CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2991654-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10065967-B2 | Compounds that are ERK inhibitors | Merck, Sharp & Dohme Corp. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3052096-A1 | INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2991654-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | TYMS 2033/4885MAPT 3528/4885ALDH1A1 450/4885 |
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | TYMS 3192/4885MAPT 2530/4885ALDH1A1 2763/4885 |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | TYMS 3192/4885MAPT 2530/4885ALDH1A1 2763/4885 |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | TYMS 2384/4885MAPT 3700/4885ALDH1A1 560/4885 |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | TYMS 3192/4885MAPT 2530/4885ALDH1A1 2763/4885 |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | TYMS 3192/4885MAPT 2530/4885ALDH1A1 2763/4885 |
| US-10065967-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | TYMS 2033/4885MAPT 3528/4885ALDH1A1 450/4885 |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAP3K20, MAPK6 | TYMS 2153/4885MAPT 3652/4885ALDH1A1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.